[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 5, 2016

Deutetrabenazine for Treatment of Chorea in Huntington Disease

Author Affiliations
  • 1University of California, San Francisco
JAMA. 2016;316(1):33-35. doi:10.1001/jama.2016.8011

In this issue of JAMA, the Huntington Study Group (HSG), First-HD study investigators, reports findings from a randomized trial examining use of a deuterated form of tetrabenazine, called deutetrabenazine, for treatment of chorea in patients with Huntington disease.1 Tetrabenazine, a vesicular monoamine transporter type 2 inhibitor that depletes monoamines including dopamine, is used worldwide for the treatment of chorea and dystonia. Tetrabenazine was approved by the US Food and Drug Administration (FDA) for the treatment of chorea in Huntington disease, based on a prior HSG study.2

First Page Preview View Large
First page PDF preview
First page PDF preview